MR-L2

• Description:

  MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5) . MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC50 of 1.2 μM[1].

• UNSPSC:

  12352005

• Target:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/mr-l2.html

• Purity:

  98.63

• Solubility:

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles:

  ClC1=C(F)C=C(C2=NN(CC(NCC3=CC(Cl)=CC(Cl)=C3)=O)C(CC)=N2)C=C1

• Molecular Formula:

  C19H16Cl3FN4O

• Molecular Weight:

  441.71

• References & Citations:

  [1]Omar F, et al. Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proc Natl Acad Sci U S A. 2019 Jul 2;116 (27) :13320-13329.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PDE4

• CAS Number:

  2374703-19-0